Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Wermke

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
Blood|May 2, 2015
RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drugMartin Wermke, Aylin Camgoz, Maciej Paszkowski-Rogacz, et al.
The Lancet. Oncology|September 11, 2025
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b studyKelly G Paulson, Sally C M Lau, Myung-Ju Ahn, et al.
Cancer Discovery|September 4, 2025
Histologic Transformation in Cancer: The Path for Clinical TranslationIoannis Vathiotis, Avisek Banerjee, Utsav Sen, et al.
Journal for Immunotherapy of Cancer|October 24, 2018
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trialChristophe Le Tourneau, Christopher Hoimes, Corrine Zarwan, et al.
Annals of Hematology|August 12, 2016
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5qEkaterina Balaian, Claudia Schuster, Claudia Schönefeldt, et al.
International Journal of Molecular Sciences|February 10, 2024
In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of CryopreservationGenqiao Jiang, Brigitte Neuber, Angela Hückelhoven-Krauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2012
MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantationMartin Wermke, Anne Schmidt, Jan Moritz Middeke, et al.
Stem Cells (Dayton, Ohio)|September 30, 2015
Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term OutcomeFelix von Dalowski, Michael Kramer, Martin Wermke, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 29, 2014
Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysisPhilippe Armand, Haesook T Kim, Johanna M Virtanen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 25, 2018
Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell TransplantationJan M Middeke, Frederike Kollinger, Henning Baldauf, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Blood|May 2, 2015
RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drugMartin Wermke, Aylin Camgoz, Maciej Paszkowski-Rogacz, et al.
The Lancet. Oncology|September 11, 2025
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b studyKelly G Paulson, Sally C M Lau, Myung-Ju Ahn, et al.
Cancer Discovery|September 4, 2025
Histologic Transformation in Cancer: The Path for Clinical TranslationIoannis Vathiotis, Avisek Banerjee, Utsav Sen, et al.
Journal for Immunotherapy of Cancer|October 24, 2018
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trialChristophe Le Tourneau, Christopher Hoimes, Corrine Zarwan, et al.
Annals of Hematology|August 12, 2016
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5qEkaterina Balaian, Claudia Schuster, Claudia Schönefeldt, et al.
International Journal of Molecular Sciences|February 10, 2024
In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of CryopreservationGenqiao Jiang, Brigitte Neuber, Angela Hückelhoven-Krauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2012
MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantationMartin Wermke, Anne Schmidt, Jan Moritz Middeke, et al.
Stem Cells (Dayton, Ohio)|September 30, 2015
Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term OutcomeFelix von Dalowski, Michael Kramer, Martin Wermke, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 29, 2014
Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysisPhilippe Armand, Haesook T Kim, Johanna M Virtanen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 25, 2018
Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell TransplantationJan M Middeke, Frederike Kollinger, Henning Baldauf, et al.
Pageof 9